Cardinal Health (CAH)
(Delayed Data from NYSE)
$112.51 USD
-1.33 (-1.17%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $112.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
CAH 112.51 -1.33(-1.17%)
Will CAH be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CAH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CAH
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
CAH: What are Zacks experts saying now?
Zacks Private Portfolio Services
CAH Stock May Gain Following the Distribution Deal With T2 Biosystems
Cardinal Health (CAH) Stock Moves -0.2%: What You Should Know
Reasons to Retain Cardinal Health Stock in Your Portfolio Now
Other News for CAH
Dividend Champion, Contender, And Challenger Highlights: Week Of October 13
November 29th Options Now Available For Cardinal Health (CAH)
Cardinal Health (CAH) Secures $1 Billion Credit Agreement and Expands Commercial Paper Program
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
UBS’ highest and lowest scoring ‘quantamental signal’ ideas